APP下载

BREAKING WITH TRADITION

2011-10-14ByLIUXINLIAN

Beijing Review 2011年22期

By LIU XINLIAN

BREAKING WITH TRADITION

By LIU XINLIAN

Traditional Chinese medicine gets banned from Europe,causing the domestic medicinal industry to rethink its strategy for sound development and going global

As Chinese companies take leaps and bounds to expand their businesses abroad, one of the country’s most treasured cultural products, traditional Chinese medicine (TCM), is having a hard time hitching a ride on the“going global” bandwagon.

Recently, TCM products have all been shut out of the European market due to technicalities and new marketing requirements.

The ban from the EU market came after the seven-year transition period of the 2004 EU Traditional Herbal Medicinal Products Directive ended on April 30. All TCM producers failed to obtain medicinal licenses,due to high costs and dif fi culties in meeting the EU Directive’s criteria.

Barriers to Europe

Chengdu-based Sichuan Neautus Traditional Chinese Medicine Co. Ltd.stopped exporting its widely known products to the European market as early as a year ago because of one of the stipulations of the EU herbal medicine directive: the registration fee.

“The registration fee is too high. We just can’t afford it,” said Xiong Shichao,Deputy General Manager of Neautus. The registration costs about 1 million yuan($153,031).

The EU Directive also stipulates that a company should demonstrate the safety and effectiveness of its herbal medicines through traditional use within the EU for at least 15 years. But TCM did not enter the EU market until the mid-1990s.

It’s difficult for Chinese TCM makers to provide the 15-year evidence that the herbal remedies are fi t for consumption, said Liu Zhanglin, Vice Chairman of the China Chamber of Commerce for Import and Export of Medicine and Health Products.

Domestic TCM producers regrettably lacked the business sense to keep product sales records stretching back that far.

Even domestic time-honored producers such as Tongrentang cannot provide evidence to prove that their products have been available in the EU market for 15 years.

Limited impact

It seems that Chinese TCM producers are not upset about being denied access from the EU, the world’s largest herbal medicine market.

Last year, the annual turnover of herbal medicine in the EU, the world’s largest herbal medicine market, stood at about 10 billion euros ($14.5 billion), accounting for more than 40 percent of the world’s total.

But China’s TCM exports last year were $1.94 billion, according to the China Chamber of Commerce for Import and Export of Medicine and Health Products.Among this total, only 14 percent were exported to the EU.

REMEDY MAKERS: Pharmacists are busy preparing medicines for clients in a drug store of Huqingyutang,a famous TCM store, based in Hangzhou, capital of Zhejiang Province

“Europe is not the main TCM export market of Zhejiang TCM producers,therefore, the ban does not affect us,” said Yao Zhaili, General Manager of Zhejiang Medicines and Health Products Trade Co.Ltd.

“For most TCM exporters, Asia is the main market, especially Japan and South Korea,” said Guo Fanli, a pharmaceutical industry analyst with CIConsulting, an industry research company.

“Most of China’s TCM producers are small and only target local markets. Few even target markets outside their own provinces, not to mention overseas markets,” said Guo

According to Zhangshu City of Jiangxi Province, a major herbal medicine center in the southern part of China, its main business income from herbal medicine reached 5 billion yuan ($769 million) last year, but its herbal medicine exports were only valued at$200,000.

Challenges remain

Despite the fact that the EU Directive may not take that great a toll on China’s TCM exporters, their small trade volume points to the herbal medicine industry’s inability to gain a foothold in the world market.

Even though China is able to sell some of its best herbal medicines, if only on a small scale, to foreign countries, most of them are raw materials and have low added value, said Yang Dianxing, Director of Administration of Traditional Chinese Medicine of Sichuan Province.

“Although China boasts a firm understanding of herbal medicines, the overall lack of industrial guidance and support for innovation and research has caused the industry to squander its resources,” said Zhao Juning,Deputy Director of the Sichuan Academy of Chinese Medicine Sciences.

“Just knowing how to make a great product doesn’t ensure that the TCM industry will grow and be successful,” said Zhao.

China’s fragmented TCM industry is the root cause for inadequate innovation and weak competitiveness, said Zhu Yonghong,Vice President of Tasly Research Institute af fi liated to the Tianjin-based Tasly Group,one of China’s largest TCM and pharmaceutical companies.

Since research and development of new drugs requires a hefty investment, small medicine producers, accounting for 80 percent of TCM producers, are unable to undertake such risky business ventures. Many of the larger companies, with larger fi nancial reserves, lack the innovation necessary to develop new drugs, said Zhu.

Another roadblock is TCM’s classi fi cation in foreign markets as food, rather than herbal medicine.

According to Yu Yuqi, President of Wenshan Miaoxiang Notoginseng Industry Co. Ltd. of Yunnan Province, his company exports notoginseng to Japan as an “organic food.” The final products will be sold after further processing in Japan.

When TCM entered the EU market in the mid-1990s, it was sold as food supplements instead of drugs.

In addition, cultural differences can’t be neglected. TCM, which focuses on remedying causes rather than treating symptoms, is supported by a strong culture of consumer

Push to go global

Another roadblock is TCM’s classification in foreign markets as food, rather than herbal medicine trust rather than lab experiments and ingredient analysis as is the case in Western drugs.

“There is an inherent prejudice against TCM in the West. Most patients still don’t believe they are real drugs and have concerns about the use of animal parts in them,” said Luo Yang, a TCM analyst from the China Chamber of Commerce for Import and Export of Medicines and Health Products.

Germany, for example, does not allow the use of animal parts in medicine, but for many famous Chinese medicines, animal parts, such as snake gall, are important ingredients, said Luo.

TCM prescriptions also focus more on the patient than the actual medical condition for which it is being prescribed. Chinese doctors give different TCM prescriptions to different patients with the same disease, said Luo.

Despite past difficulties and the industry’s general inexperience, experts are calling on TCM companies to pool their resources and collectively seek to explore the global market.

To assist these efforts, the Ministry of Health launched an industry-university alliance last August to promote TCM in the global market. The alliance aims to introduce international standards to domestic TCM manufacturers to pave the way for easier registration in overseas markets.

“Registration and consumer acceptance are going to be crucial if Chinese medicines are going to enter Western markets,” said Luo.

China has signed 91 government contracts with 70 countries to cooperate in the general medical sector, plus 48 contracts exclusively concerned with TCM, according to Peng Yuhang, an of fi cial with the Sichuan Provincial Science and Technology Department.

Industry insiders think the government needs to play a role in promoting TCM in the global market and China should learn from South Korea’s publicity strategies, which has sent government delegates to promote its ginseng in China.

They also suggested Chinese TCM enterprises cooperate with local medicine producers in foreign countries.

“Chinese TCM exporters could get to know overseas markets by cooperating with local foreign companies,” said Li Jizong, Director of the Industry Promotion Department of Shanghai Technological and Industrial Promotion Center for TCM.

Lin Bin, director of a TCM clinic in the Netherlands, suggested that China’s domestic TCM companies develop long-term goals and cooperate with local competitors in foreign markets.

They should also establish partnerships with prestigious European medical institutions specializing in research and development, said Lin.

TCM TIME: Two TCM clinics are opened in Leeds, Britain. TCM has gained increasing popularity around the world in recent years